武田制药公布新关键性研究数据显示Oveporexton改善1型发作性睡病患者的日常功能、认知及夜间睡眠

美通社
Jun 16

在第40届美国联合专业睡眠学会年会(SLEEP 2026)上公布的3期研究次要及探索性终点结果显示,Oveporexton在广泛的日间及夜间症状方面带来改善 武田制药正按计划推进全球监管申报,有望将首个且唯一的食欲素激动剂[6]带给1型发作性睡病患者 日本大阪和马萨诸塞州剑桥2026年6月16日 /美通社/ -- 武田制药(TSE:4502/NYSE:TAK)6月15日在第40届美国联合专业睡眠...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10